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Mortality is an important endpoint in chronic obstructive pulmonary disease (COPD) trials,
although accurately determining cause of death is difficult. In the Understanding the Potential
Long-term Impacts on Function with Tiotropium (UPLIFT) trial, a Mortality Adjudication
Committee (MAC) provided systematic, independent and blinded assessment of cause-
specific mortality of all 981 reported deaths. Here we describe this process of mortality adju-
dication and methodological revisions introduced to help standardise the adjudication of two
areas recognised to pose particular difficulty; firstly, the classification of fatal COPD exacerba-
tions that occur in the setting of pneumonia and secondly, the categorisation of sudden death.
In addition MAC determined cause of death was compared with that reported by site investi-
gators (SIs). MAC-assigned causes of death were: respiratory, 35%; cancer, 25%; cardiovascular,
11%; sudden cardiac death, 4.4%; sudden death, 3.4%; other, 8.8%; unknown, 12.4%. Cancer/
cardiac deaths were more common in Global Initiative for Chronic Obstructive Lung Disease
stage II, respiratory deaths in stages III and IV. Agreement between MAC and SI regarding cause
of death was complete (50.2%), incomplete (18.5%) or none (31.3%). The SI classified deaths as
cardiac three-fold more frequently than MAC (incidence rate [IR]/100 patient-years 0.797 vs.
0.257), although IR ratios for cardiac deaths for tiotropium vs. control were similar between SI
and MAC. Discrepancies between MAC- and SI-adjudicated causes of death are common, espe-
cially increased reporting of cardiac deaths by the SI. Future multicentre COPD trials should
plan appropriate infrastructure before study initiation to ensure collection and interpretation
of fatal events data.
ª 2011 Elsevier Ltd. All rights reserved.90263 178; fax: þ44 28 90329 899.
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one dose of study medication. The MAC, comprising threeDetermining the precise cause of death in patients with
chronic obstructive pulmonary disease (COPD) can be
difficult due to comorbid disease, complex clinical
scenarios at the time of death and the failure by attending
physicians to take into account the contribution of COPD.
Historically, information on cause of death has been ob-
tained from death certificates, although significant
concerns exist regarding their accuracy.1e3 Accurate
determination of cause of death is important in clinical
trials and, to address this, physician panels have been
routinely used in cardiovascular (CV) trials to review death
documentation independently and systematically and
assign cause-specific mortality.4,5 In the context of trials
designed to assess treatment efficacy and safety, regula-
tory authorities derive confidence in the validity of results
when central adjudication is undertaken.6 While cause-
specific mortality has been reported for patients with
COPD admitted to hospital7 and COPD participants in
a large smoking cessation trial,8 it is only recently that
methodology for a systematic adjudication process has
been described and evaluated.9
In the Understanding the Potential Long-term Impacts on
Function with Tiotropium (UPLIFT) trial, a Mortality
Adjudication Committee (MAC) was established to provide
a systematic, independent and blinded assessment of
cause-specific mortality in a large global trial investigating
the effect of the long-acting anticholinergic, tiotropium,
over 4 years in patients with COPD. The study design has
been described previously10 and the results, including the
effect of tiotropium on mortality, have been published.11,12
Here we describe the process of mortality adjudication
in the UPLIFT trial and highlight differences from previ-
ously described methodology.9 In particular, we report on
methodological revisions designed to help standardise the
adjudication of two areas recognised to pose particular
difficulty; firstly, the classification of fatal COPD exacer-
bations that occur in the setting of pneumonia and,
secondly, the tendency to categorise sudden death or
unwitnessed deaths (with no readily identifiable cause)
solely as a CV event. In addition, we report on the nature
and extent of discrepancies in death adjudication between
MAC and site investigator (SI). In doing so, we offer
recommendations for the adjudication of cause-specific
mortality in large multicentre COPD trials in the future.
Methods
UPLIFT study design
The UPLIFT study design has been described previously10
(refer to e-Methods for an overview). Briefly, UPLIFT was
a 4-year multicentre, multinational, double-blind, rando-
mised, placebo-controlled, parallel-group study of the
effects of the once-daily inhaled anticholinergic, tio-
tropium, on the rate of decline in lung function in COPD
patients. Secondary endpoints included health-related
quality of life, exacerbations and all-cause and respira-
tory mortality. A total of 5992 study participants (from 37
countries and 490 investigational sites) with a clinicaldiagnosis of COPD were randomised and received at least
physicians (LMG, DN, SM) with clinical and research expe-
rience in internal, pulmonary and critical care medicine
with one (SM) having additional expertise in cardiology,
independently and centrally adjudicated the cause of
death for all reported deaths in the study between
screening of the first patient and database lock. A total of
989 deaths were centrally adjudicated, which included
eight deaths in patients who were not randomised and had
never received study drug. There were 981 deaths among
randomised participants, of which 921 deaths occurred
during the protocol-defined treatment period (1440 days).
This paper describes the findings following attribution of
cause-specific mortality analyses of all 981 reported deaths
in the randomised population without censoring the data.MAC documentation and adjudication processes
The process of acquiring death documentation and MAC
adjudication are described in depth in the e-Methods
section. A schematic of the adjudication process has been
provided in e-Appendix 1. In brief, when a study site was
made aware of the death of a participant, a serious adverse
event report was compiled, which detailed all information
on the fatal adverse event including, where available, the
death certificate, hospital discharge summary and other
hospital records (pathology, radiology and laboratory data).
In cases of “out of hospital” death, the site coordinator or
site physician attempted to ascertain information from
witness interviews (more details in e-Appendix 2).Determination and categorisation of specific cause
of death
The MAC developed their principles of operation (e-
Appendix 2) for the determination of cause of death at an
initial organisational meeting, based on discussion around
hypothetical clinical scenarios of likely deaths in COPD
patients and a review of procedures from the previously
published Towards a Revolution in COPD Health (TORCH)
trial.9 The primary cause of death, as determined by the
MAC, was grouped into one of the following general cate-
gories: respiratory; CV; cancer; sudden cardiac death;
sudden death; other cause; unknown. For each category,
other than those classified as sudden cardiac death, sudden
death or unknown, a specific diagnosis (i.e., COPD exac-
erbation, myocardial infarction, lung cancer, etc.) was
determined by the MAC. A copy of the adjudication form
used in the study can be found in e-Appendix 3. The
UPLIFT study mortality analysis was based on the MAC-
determined cause of death as coded using the Medical
Dictionary for Regulatory Activities (MedDRA) version 11.0,
under one of the predefined system organ class (SOC) and
preferred term (PT).
In an attempt to address a number of areas that posed
diagnostic difficulty in the TORCH trial, some additional
modifications to the definition of COPD exacerbation and
sudden death were made a priori in the UPLIFT trial, as
follows.
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pneumonia
A COPD exacerbation was determined as the cause of death
by the MAC in the setting of typical symptoms and clinical
signs coupled with standard treatment measures. A diag-
nosis of pneumonia in the presence of an exacerbation of
COPD was determined by documented evidence of typical
symptoms and clinical findings, together with chest radi-
ology (lung infiltrate) with or without laboratory findings.
However, “pneumonia” was accepted by the MAC if the
diagnosis was made by providers in a hospital facility, even
though radiographic documentation was not available for
the MAC to review. Cases were therefore categorised as:
“COPD exacerbation with pneumonia”, “without pneu-
monia” or “pneumonia not specified”.
Adjudication of sudden death
Sudden death is a term generally denoting a presumed
arrhythmic death when the death is witnessed and another
cause cannot be identified. However, it is more likely that
the cause is cardiac in nature if the death (not necessarily
witnessed) occurred within a reasonable time frame (i.e.,
less than 1 h) of the patient last being seen alive and
without evidence of clinical deterioration.2 Therefore, for
the purpose of adjudication, death with no other identifi-
able cause was considered to be an unexpected death in
a stable patient and categorised as either:
i) Sudden cardiac death: Unexpected death occurring
within 1 h of an abrupt change of a person’s clinical
state without other obvious noncardiac cause. The MAC
recognised that not all sudden deaths in this category
were attributable exclusively to a CV cause; or
ii) Sudden death: Unexpected death occurring more than
1 h and less than 24 h of the patient last being observed
alive and without evidence of a deteriorating medical
condition.Table 1 Baseline patient characteristics by mortality
status.
Survived Died
Number of patients 5011 981
Mean agea 63.84 (8.4) 67.93 (7.8)
BMIa 26.19 (5.0) 24.85 (5.3)
Sex [% female/male] 26/74 20/80
Smoker [% current/ex] 29/71 30/70
Mean pre-bronchodilator
FEV1 [L]
a 1.12 (0.4) 0.96 (0.4)
FEV1/FVC 42.95 (10.4) 38.87 (10.5)
FEV1 [% predicted]
a 40.16 (11.9) 35.56 (12.0)
Mean post-bronchodilator
FEV1 [L]
a 1.36 (0.4) 1.14 (0.4)
FEV1/FVC
a 44.15 (10.6) 39.82 (10.8)
FEV1 [% predicted]
a 48.55 (12.4) 42.50 (13.0)
a Mean (standard deviation). BMI: body mass index, FEV1:
forced expiratory volume in 1 s, FVC: forced vital capacity.Comparison of the classification of cause of death
between SI and MAC
The diagnostic term for the cause of death, as entered in
the case report form by the SI or determined by the MAC
using their predefined adjudication process was coded using
PTs from MedDRA version 11.0, which were also grouped
under predefined SOCs. Event incidence rates (IRs) were
determined for each SOC and PT and were compared
between MAC and SI.
Reliability of adjudication procedure
In order to assess the reliability of the committee’s
assessments, the MAC agreed to a process where approxi-
mately 10% of the fatal cases were randomly selected from
each session and submitted for readjudication. These cases
were combined with other cases in a manner that made
them indistinguishable from the cases not yet assessed.Statistics
All randomised and treated patients were included in the
analysis. The baseline characteristics of patients who
survived or died during the study were summarised
descriptively. Frequency distributions of adjudicated cau-
ses by Global Initiative for Chronic Obstructive Lung Disease
(GOLD) stage were generated. Adverse event IRs were
calculated as the number of patients with at least one
event divided by the time at risk and expressed per 100
patient-years. To evaluate the reliability of the adjudica-
tion process, 96 fatal cases (9.8%) were randomly selected
for readjudication and consistency was evaluated using the
Kappa statistic.Results
There were 981 deaths in the randomised population
reviewed by the MAC during nine central adjudication
meetings held between July 2007 and May 2008. The
demographics of the decedent population compared with
survivors are displayed in Table 1. In 92% of the cases, an
agreement on the cause of death was reached on review of
the Council for International Organisations of Medical
Sciences’ (CIOMS) narrative and other supporting docu-
ments initially presented to the MAC. In 8% of the cases,
additional information was requested by the MAC to enable
a final adjudication. A unanimous agreement on the
primary cause of death was reached in all cases except in
one. Documentation of the fatal event was limited in the
31% of cases that were requested from prematurely dis-
continued patients during the vital status collection
process.
The adjudicated cause of death as categorised by the
MAC for the total randomised population and by GOLD stage
is displayed in Fig. 1 and Table 2, respectively. There were
notable shifts in the proportions of these categories when
analysed for GOLD stage of severity. Among GOLD stage II
patients, cancer and cardiac were the most common
Figure 1 Classification of deaths by the MAC. Total number
of deaths Z 981, Number of deaths in each category is
provided below the cause of death. CV: cardiovascular, MAC:
Mortality Adjudication Committee, SCD: sudden cardiac death,
SD: sudden death.
Table 2 Summary of adjudicated cause of death classified
by GOLD stage.
Cause of death (%) GOLD stage
II N Z 298 III N Z 496 IV N Z 166
Respiratory 16.8 37.5 59.0
Cancer 37.6 24.6 12.0
CV 14.4 8.3 5.4
Sudden cardiac
death
5.7 4.0 1.8
Sudden death 2.3 4.6 1.8
Other causes 12.8 7.3 4.8
Unknown 9.7 13.5 14.5
CV: cardiovascular, GOLD: Global Initiative for Chronic
Obstructive Lung Disease.
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commonly represented in GOLD stage IV. The most
commonly reported causes of death (1% of total) by SOC
and PT are provided in Table 3.
Determination of pneumonia in association with
a COPD exacerbation
A COPD exacerbation was assigned as the primary cause of
death by the MAC in 276 cases. Of these, only 63 had
sufficient information available on which the MAC could use
the predefined criteria (e-Appendix 2), to determine if
pneumonia was associated or not. The MAC determined
that pneumonia was present in 50 of these 63 cases.
Adjudication of sudden death
Unexpected deaths occurring in stable patients within 1 h
(defined as “sudden cardiac death”) or more than 1 h and
less than 24 h (defined as sudden death) of last been
observed alive and without evidence of deteriorating
medically were determined in 4.4% and 3.3% of cases,
respectively.
Comparison of the classification of cause of death
between SIs and MAC
There was complete agreement between SIs and MAC at
both the SOC and PT level in 493 (50.2%) cases, incomplete
agreement (i.e., either at SOC or PT level) in 181 (18.5%)
cases and complete disagreement in 307 (31.3%) cases. The
IRs (per 100 patient-years) for most SOC categories were
similar between SIs and MAC (Table 3). The major exception
was a three-fold greater IR for “cardiac disorders” based on
SI classification compared to the MAC (0.797 vs. 0.257). The
shift in SOC between the SI-reported and MAC-determined
primary cause of death for the most common SOCs is dis-
played in Table 4. Deaths attributed to cardiac disorders bySIs but categorised as “general” or “respiratory (lower)” by
MAC accounted for most of the discrepancy. However,
these differences had no significant effect on treatment-
related rate ratios for any of the SOC categories (Fig. 2).
The relative risk for “cardiac disorders” between tio-
tropium and placebo was 0.81 (95% confidence interval [CI],
0.60e1.10) for SI and 0.80 (95% CI, 0.76e0.99) for MAC.
Reliability of the adjudication process
There were 96 (9.8%) cases randomly selected and
submitted for blind readjudication during the course of the
meetings. An identical adjudication on the cause of death
was reached in 89.6% cases with a Kappa value of 0.89 (95%
CI, 0.83e0.96).
Discussion
In this study, we have reaffirmed that a MAC can provide an
independent, standardised and reproducible determination
of cause-specific mortality in a large, long-term, multina-
tional, multicentre clinical trial. We also report three
additional findings: firstly, we confirm that unexpected
sudden death occurs relatively commonly in COPD patients
(7.7% of fatal cases of the randomised patients in UPLIFT)
and appears independent of disease severity; secondly,
pneumonia is frequently associated with fatal exacerba-
tions of COPD (present in 50 of 63 cases where radiological
determination was possible); finally, differences in the
classification of cause of death by SI and MAC are common
and occurred in almost half of the cases in this study. Most
notably, SIs were three times more likely than the MAC to
assign a cardiac cause of death, although this did not alter
the between-treatment differences in the UPLIFT study.
The UPLIFT data suggest striking shifts in the proportions
of adjudicated category of death with COPD severity. In
COPD patients with GOLD stage II disease, cancer and, in
particular, lung cancer predominates. Not surprisingly,
respiratory causes of deathwere common across all stages of
severity but dominant in GOLD stage IV. Furthermore, in this
most severe stage of disease, theMACdetermined that death
was related to COPD in almost 60% of cases compared with
fewer than 20% in the GOLD stage II category. These findings
Table 3 Overall SOC and preferred term cause of death
reported in 1% of fatal events.
SOC/PT IRa SI IRa MAC
Cardiac disorders 0.797 0.257
Cardiac arrest 0.106
Cardiac failure 0.106
Cardiac failure acute 0.032
Cardiac failure congestive 0.060 0.138
Cardiorespiratory arrest 0.051
Cardiopulmonary failure 0.074
Myocardial infarction 0.193 0.101
Gastrointestinal disorders 0.046 0.069
General disorders and
administration site conditions
0.689 0.875
Death 0.515 0.525
Multi-organ failure 0.046
Sudden cardiac death 0.009 0.197
Sudden death 0.083 0.151
Infections and infestations 0.170 0.050
Sepsis 0.078 0.028
Septic shock 0.046
Injury, poisoning and
procedural complications
0.046 0.092
Neoplasms benign,
malignant and unspecified
0.333 0.373
Colorectal cancer 0.005 0.060
Nervous system disorders 0.147 0.165
Cerebrovascular accident 0.074 0.142
Respiratory system disorders (lower) 1.315 1.474
Acute respiratory failure 0.051
COPD exacerbation 0.473 1.217
Emphysema 0.046
Pneumonia 0.212 0.239
Respiratory failure 0.389
Respiratory system disorders (other) 0.629 0.767
Bronchial carcinoma 0.051
Lung neoplasm malignant 0.212 0.674
Pulmonary embolism 0.069 0.032
Vascular disorders 0.074 0.064
a IR expressed per 100 patient-years. COPD: chronic obstruc-
tive pulmonary disease, IR: incidence rate, MAC: Mortality
Adjudication Committee, PT: preferred term, SI: site investi-
gator, SOC: system organ class.
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mild13 and severe COPD patients.7 Interestingly, in the
UPLIFT study, the frequency of unexpected (sudden) death
did not appear to be influenced by disease severity.
In the TORCH trial, a number of areas of adjudication
proved problematic: firstly, the adjudication of an unex-
pected or sudden death; secondly, determining the rela-
tionship of pneumonia to a fatal exacerbation of COPD;
and, thirdly, the collection of vital status data on partici-
pants who discontinued prematurely from the study.
When sudden death is witnessed or has occurred within
1 h of the study participant last being seen alive and clin-
ically stable, it is commonly attributed to CV causes,
particularly arrhythmias in the setting of established coro-
nary artery disease.14 However, the primary cause of deathshould not necessarily be categorised a priori as cardiac, as
COPD patients may develop an arrhythmia in the absence of
significant coronary disease as a consequence of severe
hypoxic respiratory failure.15 In TORCH, a diagnosis of
sudden death was common (16%) but the definition used in
that study was broad (i.e., unexpected death within 24 h of
last being seen alive in a stable state). As there is no
consensus on the definition of sudden deaths in COPD
patients, we felt it was important to refine the definition of
sudden death by characterising the event by time trends in
this study. Therefore, we distinguished between sudden
death occurring less than 1 h of last being observed alive
and without evidence of a deteriorating medical condition,
and sudden death occurring more than 1 h after but less
than 24 h prior to last being observed alive and without
evidence of a deteriorating medical condition. The former
definition has been recognised to more accurately repre-
sent a “probable” cardiac death.16 We recommend the use
of these more precise definitions in future COPD clinical
trials and believe they may limit the instances when
a sudden death is inaccurately categorised solely as a CV
event. We suggest that study coordinating staff and SIs be
trained in establishing the nature and timing of events
preceding an unexpected sudden death in future trials.
Individuals with COPD are at increased risk of developing
pneumonia17 and recent clinical trials suggest that long-term
therapywith inhaled corticosteroidsmay increase this risk.18
In UPLIFT, we attempted to evaluate the frequency with
which pneumonia was associated with a fatal COPD exacer-
bation.Wewere only able to subclassify COPD exacerbations
confidently as “with” or “without” pneumonia in approxi-
mately 23% of cases due to the limited documentation of
a chest radiograph. To improve the understanding of the
pathophysiological consequences of pneumonia in COPD and
to improve pharmacovigilance in clinical trials, we recom-
mend that a chest radiograph be mandated by the study
protocol when pneumonia is suspected.
A protocol amendment was made during the course of
the UPLIFT trial to include the collection of vital status
data on participants who discontinued prematurely from
the study. Although similar adjudication procedures were
employed, acquiring death documentation often proved
a challenge because of legal restrictions in some jurisdic-
tions. Most of the vital status cases had limited or no
information available on the circumstances surrounding the
death; consequently, the cause of death was unknown in
approximately 25% of cases. In the future, those designing
large, international, multicentre clinical trials should
consider the necessary ethical and legal issues likely to
arise in following the cohort who has discontinued trial
medication prematurely.
Discrepancies between MAC- and SI-assigned cause of
death were common. Most striking was a three-fold
increase in the reporting of a cardiac cause of death by SI
compared to the MAC. A proportion of this discrepancy can
be attributed to our study methodology, whereby a MAC-
assigned “sudden cardiac death” or ”sudden death” is
coded to “general disorders” using MedRA classification
system, whereas SI-reported “cardiac arrest” or “cardio-
pulmonary arrest” codes to “cardiac disorders”. Even if we
assume that all our cases of “sudden cardiac death” and
“sudden death” were in fact cardiac, there still remains
Table 4 Shift in SOC between reported and adjudicated primary cause of death (most common SOCs shown). Shaded boxes
indicate concordance.
SOC reported by MAC
Cardiac General Neoplasms Respiratory (lower) Respiratory (other) Other SOCs Total
Total 60 198 90 336 175 122 981
SOC reported by
investigator
Cardiac 55 54 3 54 4 7 177
General 2 121 1 16 8 12 160
Neoplasms 0 0 72 0 6 1 79
Respiratory (lower) 1 14 6 241 18 14 294
Respiratory (other) 0 3 2 7 128 2 142
Other SOCs 2 6 6 18 11 86 129
SOC: system organ class, MAC: Mortality Adjudication Committee.
520 L.P. McGarvey et al.a substantial shift of death from cardiac causes to death
from respiratory causes when comparing SI with MAC
mortality adjudication (see Table 4). A preferential cate-
gorisation of a COPD death as cardiac by the SI was also
observed in the TORCH trial; together with the results from
UPLIFT, this may reflect a general tendency by SIs to
report the mechanism of death (e.g., cardiac arrest) rather
than the underlying cause of death. While this difference
did not alter the interpretation of the between-treatment
analyses in the UPLIFT trial, we suggest that suchFigure 2 Treatment-related rate ratios for cause of death b
Committee, SOC: system organ class.discrepancies could alter the interpretation of a trial where
a smaller difference in treatment effect exists.19,20
While all-cause mortality remains a key outcome
measure in clinical trials of COPD therapy, the reliable
categorisation of cause of death has important implica-
tions. Firstly, it is desirable to ascertain that the treatment
intervention has prevented COPD deaths without concomi-
tant increases in deaths from other causes (e.g., cardiac).
Secondly, regulatory authorities derive confidence in the
validity of results when central adjudication is performedy SOC. CI: confidence interval, MAC: Mortality Adjudication
Mortality adjudication in a large COPD trial 521and, finally, establishing exactly what COPD patients die
from may help clarify the complex inter-relationships
between comorbidities and mortality.
In summary, we reaffirm that a MAC can provide a stand-
ardised and systematic approach to mortality adjudication,
and highlight the importance of planning for follow-up to
ascertain vital status of all trial participants, the identifica-
tion of appropriate resource to collect clinical data
surrounding fatal events and the relevance of predefined
standardised definitions for events of particular interest.
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